论文部分内容阅读
目的:研究人类乳腺癌组织中与张力蛋白同源第10号染色体缺失的磷酸酶基因(PTEN)和过氧化物酶体增长因子活化受体γ(PPARγ)蛋白及其与相关分子病理学指标表达的关系和临床意义,为乳腺癌的分子病理分型提供基础研究依据。方法:随机选取我院临床证实66例乳腺癌患者的临床资料及病理切片,利用免疫组织化学链霉素抗生物素-过氧化物酶(SP)法检测乳腺癌组织中PTEN、PPARγ、雌激素受体(ER)、孕激素受体(PR)、Her-2蛋白的表达,分析乳腺癌组织中PTEN和PPARγ蛋白表达与患者淋巴结转移率及Her-2、ER、PR表达之间的关系。结果:乳腺癌组织中PTEN和PPARγ蛋白表达阳性率分别为68.2%、63.6%,PTEN阳性表达主要在细胞核内,占72.86%,胞浆占27.14%,PPARγ阳性表达在核膜占87.3%。相关分析表明PTEN与PPARγ、ER、PR、HER-2表达无显著相关(P均>0.05),PPARγ与ER、PR、HER-2表达无显著相关(P均>0.05)。PTEN阳性表达乳腺癌患者淋巴结转移率为48.97%,阴性表达淋巴结转移率为46.04%。PPARγ阳性表达乳腺癌患者淋巴结转移率为53.96%,阴性表达淋巴结转移率为43.64%。结论:PTEN、PPARγ可能作为独立的乳腺癌预后标记物,对乳腺癌生物治疗和临床预后提供依据。
AIM: To investigate the expression of PTEN and PPARγ protein homologues on chromosome 10 and their correlations with related molecular pathological markers in human breast cancer The relationship and clinical significance of breast cancer molecular pathological typing provides the basis for research. Methods: The clinical data and pathological sections of 66 cases of breast cancer clinically confirmed in our hospital were randomly selected. The expression of PTEN, PPARγ, estrogen in breast cancer tissues was detected by immunohistochemical streptavidin-peroxidase (SP) ER, PR and Her-2 protein in breast cancer. The relationship between the expression of PTEN and PPARγ protein and the lymph node metastasis and the expression of Her-2, ER and PR in breast cancer was analyzed. Results: The positive rates of PTEN and PPARγ in breast cancer tissues were 68.2% and 63.6%, respectively. The positive expression of PTEN was mainly in the nucleus, accounting for 72.86% and cytoplasm accounting for 27.14%. The positive expression of PPARγ in nucleus accounted for 87.3%. Correlation analysis showed that there was no significant correlation between PTEN and the expression of PPARγ, ER, PR and HER-2 (all P> 0.05). There was no significant correlation between PPARγ and ER, PR and HER-2 (all P> 0.05). The rate of lymph node metastasis in PTEN positive breast cancer patients was 48.97%, and the negative rate of lymph node metastasis was 46.04%. The rate of lymph node metastasis in patients with PPARγ positive expression was 53.96%, and the rate of negative lymph node metastasis was 43.64%. Conclusions: PTEN and PPARγ may serve as independent prognostic marker of breast cancer, providing evidence for biological treatment and clinical prognosis of breast cancer.